TCGA-CV-A45V-01A-21R-A24Z-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.007305936
- sex
- female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- CHOLESTEROL_HOMEOSTASIS+0.450
- INTERFERON_ALPHA_RESPONSE+0.420
- OXIDATIVE_PHOSPHORYLATION+0.400
- NOTCH_SIGNALING+0.380
- INTERFERON_GAMMA_RESPONSE+0.350
- ADIPOGENESIS+0.340
- FATTY_ACID_METABOLISM+0.320
- P53_PATHWAY+0.310
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.310
- TNFA_SIGNALING_VIA_NFKB+0.310
Top 10 suppressed
- E2F_TARGETS-0.480
- G2M_CHECKPOINT-0.350
- PANCREAS_BETA_CELLS-0.340
- DNA_REPAIR-0.320
- HEDGEHOG_SIGNALING-0.280
- MITOTIC_SPINDLE-0.250
- SPERMATOGENESIS-0.170
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.130
- MYC_TARGETS_V1-0.120
- ANGIOGENESIS-0.070
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
1 twin match this tumor's tissue · 9 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | s_150324_7b | EPN | Posterior Fossa EPN | 0.830 |
| 2 | s_150324_8b | EPN | Posterior Fossa EPN | 0.828 |
| 3 | BS_0J9SHHSC | low-grade glioma | — | 0.822 |
| 4 | BS_WG203ECV | pilocytic astrocytoma | — | 0.791 |
| 5 | BS_2EMW8ZG3 | low-grade glioma | — | 0.791 |
| 6 | BS_YCREDZTJ | low-grade glioma | — | 0.786 |
| 7 | BS_NB5XWMJT | low-grade glioma | — | 0.783 |
| 8 | BS_3W07B2TG | subependymal giant cell astrocytoma(SEGA) | — | 0.781 |
| 9 | BS_49852ZBH | pilocytic astrocytoma | — | 0.778 |
| 10 | 20110132.TNBC | — | F | 0.771 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| CHOLESTEROL_HOMEOSTASIS | 0.450 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.420 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.400 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.380 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.350 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.340 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.320 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.310 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.310 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.310 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.240 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.230 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.220 | Idelalisib | — uncovered |
| APOPTOSIS | 0.200 | Idelalisib | — uncovered |
| HYPOXIA | 0.200 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.200 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.180 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.170 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.170 | Inavolisib | — uncovered |
| COMPLEMENT | 0.140 | Inavolisib | — uncovered |